Skin Toxicities Clinical Trial
Official title:
Development of a Functional Assessment of Side-effects to Therapy (FAST) Questionnaire to Assess Dermatology-Related Quality of Life in Patients Treated With EGFR Inhibitors: The FAST-EGFR Inhibitors: The FAST-EGFRI and Development of an Investigator Grading System: The Skin and Eye Reactions to Inhibitors of EGFR (SERIES) Score
Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities.
Clinical experience suggests that skin toxicities interfere with health related quality of
life (HRQL) and may interfere with treatment adherence. No systematic investigations of
EGFRI-associated dermatologic toxicities and impact on HRQL have been reported. No
patient-reported outcome measures exist to capture the unique concerns of oncology patients
who experience EGFRI-associated dermatologic toxicities.
The purpose of this study is to develop a patient-reported outcomes measure to assess
dermatologic-related symptoms burden and health-related quality of life among patients
receiving an EGFRI, and to develop a grading system for EGFRI-associated dermatologic
toxicities.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01380262 -
Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment
|
N/A | |
| Completed |
NCT00332163 -
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
|
Phase 2 |